Press release - 19/03/2025 Pocket-sized breath test for stomach bacteria Mini sensor analyses breath for infection with Helicobacter pylori Stomach ulcers, gastritis and even stomach cancer are often the result of an infection with Helicobacter pylori. If the bacterium remains unrecognised for a long time, this can have serious consequences. Researchers have now developed a miniaturisable sensor system for the mobile analysis of breath that is effective, fast and inexpensive. The research team uses a biological survival trick of the stomach germ to detect the bacterium. https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-breath-test-stomach-bacteria-mini-sensor-analyses-breath-infection-helicobacter-pylori
Press release - 26/05/2026 How blood stem cells diversify Different types of bone marrow stem cells give rise to blood and immune cells. A team led by Simon Haas now reports in “Nature Cell Biology” how that diversity develops. The findings could help improve stem cell therapies, including treatments for blood cancers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-stem-cells-diversify
Press release - 22/03/2024 New Emmy Noether junior research group for biological data science An Emmy Noether junior research group at Heidelberg University is investigating how to gain new insights into fundamental biological mechanisms from large-scale molecular data sets. Led by Junior Professor Dr Britta Velten, it has started work at the Centre for Organismal Studies and the Interdisciplinary Center for Scientific Computing. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-biological-data-science
Press release - 27/03/2024 Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-granted-orphan-drug-designation-fda-its-proprietary-atac-candidate-hdp-101
The Baden-Württemberg healthcare industry The biotechnology sector Baden-Württemberg is currently home to 193 biotechnology companies, most of which specialise in so-called ‘red biotechnology’ - i.e. applications in the medical and pharmaceutical sectors. The biotech sector includes not only traditional biotechnology companies, but also companies from the fields of bioinformatics, diagnostics, analytics and biotechnological production.https://www.gesundheitsindustrie-bw.de/en/location/biotech
Press release - 18/01/2021 How a protein variant could explain resistance to sleeping sickness drug A specific variant of the surface protein VSG of African trypanosomes, the causative agents of sleeping sickness, is associated with resistance to the important drug Suramin. Scientists at the German Cancer Research Center have now been able to find a possible explanation for the formation of resistance based on the crystal structure of this protein variant.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-protein-variant-could-explain-resistance-sleeping-sickness-drug
Press release - 24/05/2024 Research Training Group on Cancer Surgery: German Research Foundation approves second funding period Since 2019, the Research Training Group (RTG) "Intraoperative Multisensoric Tissue Differentiation in Oncology," a collaboration between the University of Stuttgart and the University of Tübingen, has been advancing research in medical technology. With the help of new sensor methods, the researchers want to help make surgical procedures on cancer patients safer and more effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-training-group-cancer-surgery-german-research-foundation-approves-second-funding-period
Dossier - 09/02/2015 Chemical tools for biological applications The boundaries between traditional scientific disciplines are becoming less and less distinct. Interdisciplinary cooperation is often required to study complex processes and biomolecular issues. Interdisciplinary cooperation is central to chemical biology. https://www.gesundheitsindustrie-bw.de/en/article/dossier/chemical-tools-for-biological-applications
Dossier - 09/09/2013 New trends in the field of immunology B- and T- lymphocytes along with macrophages have long been regarded as the most important cells of the human immune system and have been a major focus of research. This has now changed and it is now the dendritic cells that are regarded as the major components of the adaptive immune system. Research into innate immune defence mechanisms has become more important due to the discovery of the role of Toll-like receptors as first-line of defence.https://www.gesundheitsindustrie-bw.de/en/article/dossier/new-trends-in-the-field-of-immunology
Press release - 13/12/2024 Schizophrenia: NMI observes processes in nerve cells Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/schizophrenia-nmi-observes-processes-nerve-cells
Press release - 09/09/2026 International Research on Bioengineering of the Mitochondrial Genome While the cell nucleus contains almost all of the genome, the mitochondria – the powerhouses of the cell – have their own small genetic code. It consists of only 37 genes, which are organized in circular DNA – mtDNA, for short. Defects in the mitochondrial genome are related to incurable neurodegenerative and metabolic diseases, cancer and also aging processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/international-research-bioengineering-mitochondrial-genome
Medical image analysis - 25/09/2025 Powerful AI systems using synthetic training data AI systems for image analysis are only as good as the data on which they are trained. The Göppingen-based start-up MIRA Vision has developed a novel method for generating synthetic, photorealistic images, enabling the efficient creation of large, high-quality training datasets. An intuitive platform also allows researchers to evaluate microscopy images with ease.https://www.gesundheitsindustrie-bw.de/en/article/news/powerful-ai-systems-image-analysis-using-synthetic-training-data
Press release - 25/10/2022 Three ERC Synergy Grants For Universität Heidelberg Scientists Heidelberg University scientists are to receive three ERC Synergy Grants – three highly endowed grants of the European Research Council – for pioneering research projects by several teams working in collaboration.https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-erc-synergy-grants-universitaet-heidelberg-scientists
Press release - 09/12/2024 Brain tumour cells rapidly integrate into brain-wide neuronal circuits Researchers at the Medical Faculty of Heidelberg University and the Heidelberg University Hospital have used modified rabies viruses to label glioblastoma tumour cells and their direct cell contacts in the mouse brain. The new method showed that the tumour cells are connected to different types of nerve cells throughout the entire brain at a very early stage of the disease. https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-tumour-cells-rapidly-integrate-brain-wide-neuronal-circuits
Press release - 10/06/2026 AI Diagnoses Brain Tumors in Minutes Instead of Weeks Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-diagnoses-brain-tumors-minutes-instead-weeks
Press release - 10/08/2023 Computer-aided cell analysis for faster diagnosis of blood diseases Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples. The algorithm can help physicians diagnose blood disorders and is available as an open source method for research purposes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/computergestuetzte-zellanalyse-fuer-die-schnellere-diagnose-von-blutkrankheiten
Press release - 03/07/2024 Max Planck scientists develop cost-efficient medical imaging method Max Planck scientists will present a low-field magnetic resonance imaging (MRI) scanner in Lindau. Two researchers from the MPI for Biological Cybernetics in Tübingen, Germany, will present a model of a new low-field MRI system. It combines hyperpolarization with imaging techniques that can be run at low magnetic field strengths. The quality of the MRI images can be enhanced with the help of artificial intelligence.https://www.gesundheitsindustrie-bw.de/en/article/press-release/max-planck-scientists-develop-cost-efficient-medical-imaging-method
Press release - 09/12/2022 Epigenetic emergency switch improves defense against infections During infections, the hematopoietic system switches from normal to emergency mode. This improves the defense against the pathogens. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now found an epigenetic switch in blood stem cells and progenitor cells of mice that can trigger the switch from one mode to the other.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetic-emergency-switch-improves-defense-against-infections
Press release - 26/05/2025 Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis Scientists at the German Cancer Research Center (DKFZ) have shown in an international eye-tracking study that dermatologists not only improve their diagnostic accuracy by using explainable artificial intelligence, but also show significantly less fatigue when assessing challenging cases. The researchers were able to demonstrate this by measuring a reduction in cognitive stress indicators.https://www.gesundheitsindustrie-bw.de/en/article/press-release/explainable-artificial-intelligence-increases-accuracy-and-endurance-dermatologists-melanoma-diagnosis
Press release - 10/04/2024 Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-grants-500k-cellnroll-2023-innovation-fellowship-program
Press release - 10/07/2024 HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-raises-euro-15-million-series-c-round-advance-clinical-development-hrx-215-liver-regeneration
Press release - 28/02/2025 Early Excellence in Science Award für Ivana Winkler The Bayer Foundation's Early Excellence in Science Award 2024 in the category of Data Science goes to Ivana Winkler of the German Cancer Research Center (DKFZ). Winkler's work uncovered the unexpected effect of female reproductive capacity: the constantly recurring remodeling of the organs of the female reproductive tract during the sexual cycle leads to fibrosis and chronic inflammation over the years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-excellence-science-award-fuer-ivana-winkler
Panosome GmbH – a parasite as the basis for innovative immunotherapies - 26/08/2026 Reaching the unreachable: new approaches to challenging drug targets Modern medicines act with remarkable precision. Antibodies, for example, recognise their molecular targets much like a key fits into its corresponding lock. However, certain targets like small molecules or carbohydrates remain difficult to target. The start-up Panosome aims to eliminate these blind spots with a novel immunotherapy platform that harnesses sophisticated masters of immune evasion: trypanosomes.https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-unreachable-new-approaches-challenging-drug-targets
Press release - 03/09/2026 ERC Starting Grant for Heidelberg Neurologist and Neuroscientist Dr. Dr. Varun Venkataramani Cells of the highly aggressive brain tumor glioblastoma exhibit predatory behavior: they exploit signaling between healthy neurons and internalize portions of their contact sites. Dr. Dr. Varun Venkataramani of the Heidelberg Medical Faculty of Heidelberg University, and his research team, will investigate how glioblastoma cells benefit from this process and whether it may represent a novel therapeutic target.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-starting-grant-heidelberg-neurologist-and-neuroscientist-dr-dr-varun-venkataramani
Dossier - 31/03/2014 Peptides diverse molecules of life Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Peptides are gaining in importance as candidates for drugs.https://www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life